Scholarlink

Background <p>Schizophrenia is a complex chronic mental disorder that severely impairs patients’ social functioning and quality of life, while imposing substantial burdens on families and society. Long-acting injectable antipsychotics (LAIs) have demonstrated potential advantages in improving both symptoms and social functioning. This study investigated the effects of transitioning from oral antipsychotics (OAPS) to Paliperidone Palmitate Once-Monthly (PP1M) on symptom control, social functioning, and caregiver burden in schizophrenia patients.</p> Methods <p>From April 11 to October 31, 2024, participants were assessed monthly using the Positive and Negative Syndrome Scale-6 (PANSS-6), Brief Psychiatric Rating Scale (BPRS), and adverse effect records. The Zarit Caregiver Burden Inventory and Personal and Social Performance (PSP) scale were administered biannually.</p> Results <p>Among 95 patients completing 6-month PP1M treatment, Zarit Burden scores decreased significantly by 44.89% (<i>p</i> &lt; 0.001), while PSP scores increased by 8.60% (<i>p</i> = 0.001). Both PANSS-6 and BPRS total scores showed significant reductions (<i>p</i> &lt; 0.00238). A moderate negative correlation was observed between BPRS improvement and PSP enhancement (<i>r</i> = -0.535, <i>p</i> &lt; 0.001).</p> Conclusion <p>PP1M treatment effectively controlled symptoms, improved social functioning, and reduced caregiver burden in schizophrenia patients. The significant correlation between symptom improvement and functional recovery suggests PP1M may substantially support long-term rehabilitation and quality of life enhancement.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of paliperidone palmitate once-monthly (PP1M) in improving social functioning and reducing caregiver burden in patients with schizophrenia: a six-month follow-up study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月29日

查看全文
  • Ling Dong,
  • Xiao-Yan Liu,
  • Wen-Cai Chen,
  • Xiao-Xin Dong,
  • Fan Wang,
  • Si-Jing Chen,
  • Xiu-Jun Liu

摘要

Background

Schizophrenia is a complex chronic mental disorder that severely impairs patients’ social functioning and quality of life, while imposing substantial burdens on families and society. Long-acting injectable antipsychotics (LAIs) have demonstrated potential advantages in improving both symptoms and social functioning. This study investigated the effects of transitioning from oral antipsychotics (OAPS) to Paliperidone Palmitate Once-Monthly (PP1M) on symptom control, social functioning, and caregiver burden in schizophrenia patients.

Methods

From April 11 to October 31, 2024, participants were assessed monthly using the Positive and Negative Syndrome Scale-6 (PANSS-6), Brief Psychiatric Rating Scale (BPRS), and adverse effect records. The Zarit Caregiver Burden Inventory and Personal and Social Performance (PSP) scale were administered biannually.

Results

Among 95 patients completing 6-month PP1M treatment, Zarit Burden scores decreased significantly by 44.89% (p < 0.001), while PSP scores increased by 8.60% (p = 0.001). Both PANSS-6 and BPRS total scores showed significant reductions (p < 0.00238). A moderate negative correlation was observed between BPRS improvement and PSP enhancement (r = -0.535, p < 0.001).

Conclusion

PP1M treatment effectively controlled symptoms, improved social functioning, and reduced caregiver burden in schizophrenia patients. The significant correlation between symptom improvement and functional recovery suggests PP1M may substantially support long-term rehabilitation and quality of life enhancement.